MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- DR. REDDYS LAB - GLENMARK PHARMA
DR. REDDYS LAB vs GLENMARK PHARMA - Comparison Results
DR. REDDYS LAB Change
Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More
GLENMARK PHARMA 
Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More
Current Valuations
| DR. REDDYS LAB | GLENMARK PHARMA | DR. REDDYS LAB/ GLENMARK PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 34.3 | 14.3 | 240.0% | View Chart |
| P/BV | x | 4.7 | 2.4 | 199.9% | View Chart |
| Dividend Yield | % | 0.6 | 0.4 | 131.9% |
Financials
 DR. REDDYS LAB  GLENMARK PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DR. REDDYS LAB Mar-20 |
GLENMARK PHARMA Mar-19 |
DR. REDDYS LAB/ GLENMARK PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 3,363 | 712 | 472.6% | |
| Low | Rs | 2,352 | 484 | 486.4% | |
| Sales per share (Unadj.) | Rs | 1,054.2 | 349.6 | 301.5% | |
| Earnings per share (Unadj.) | Rs | 121.9 | 32.8 | 371.9% | |
| Cash flow per share (Unadj.) | Rs | 190.2 | 44.3 | 429.1% | |
| Dividends per share (Unadj.) | Rs | 25.00 | 2.00 | 1,250.0% | |
| Dividend yield (eoy) | % | 0.9 | 0.3 | 261.4% | |
| Book value per share (Unadj.) | Rs | 938.7 | 198.6 | 472.6% | |
| Shares outstanding (eoy) | m | 166.17 | 282.17 | 58.9% | |
| Bonus/Rights/Conversions | ESOP | - | - | ||
| Price / Sales ratio | x | 2.7 | 1.7 | 158.6% | |
| Avg P/E ratio | x | 23.4 | 18.2 | 128.6% | |
| P/CF ratio (eoy) | x | 15.0 | 13.5 | 111.4% | |
| Price / Book Value ratio | x | 3.0 | 3.0 | 101.2% | |
| Dividend payout | % | 20.5 | 6.1 | 336.1% | |
| Avg Mkt Cap | Rs m | 474,831 | 168,625 | 281.6% | |
| No. of employees | `000 | 21.7 | 12.0 | 179.9% | |
| Total wages/salary | Rs m | 33,802 | 20,561 | 164.4% | |
| Avg. sales/employee | Rs Th | 8,091.0 | 8,196.0 | 98.7% | |
| Avg. wages/employee | Rs Th | 1,561.3 | 1,708.1 | 91.4% | |
| Avg. net profit/employee | Rs Th | 935.8 | 768.5 | 121.8% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 175,170 | 98,655 | 177.6% | |
| Other income | Rs m | 6,206 | 2,081 | 298.2% | |
| Total revenues | Rs m | 181,376 | 100,736 | 180.1% | |
| Gross profit | Rs m | 24,421 | 15,858 | 154.0% | |
| Depreciation | Rs m | 11,348 | 3,259 | 348.2% | |
| Interest | Rs m | 983 | 3,346 | 29.4% | |
| Profit before tax | Rs m | 18,296 | 11,335 | 161.4% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 561 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 1,672 | 0.0% | |
| Tax | Rs m | -1,403 | 3,756 | -37.3% | |
| Profit after tax | Rs m | 20,260 | 9,250 | 219.0% | |
| Gross profit margin | % | 13.9 | 16.1 | 86.7% | |
| Effective tax rate | % | -7.7 | 33.1 | -23.1% | |
| Net profit margin | % | 11.6 | 9.4 | 123.4% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 125,991 | 66,968 | 188.1% | |
| Current liabilities | Rs m | 72,141 | 40,211 | 179.4% | |
| Net working cap to sales | % | 30.7 | 27.1 | 113.3% | |
| Current ratio | x | 1.7 | 1.7 | 104.9% | |
| Inventory Days | Days | 73 | 83 | 87.7% | |
| Debtors Days | Days | 105 | 81 | 129.0% | |
| Net fixed assets | Rs m | 83,854 | 33,322 | 251.6% | |
| Share capital | Rs m | 831 | 282 | 294.5% | |
| "Free" reserves | Rs m | 155,157 | 55,770 | 278.2% | |
| Net worth | Rs m | 155,988 | 56,052 | 278.3% | |
| Long term debt | Rs m | 1,304 | 35,738 | 3.6% | |
| Total assets | Rs m | 232,253 | 132,888 | 174.8% | |
| Interest coverage | x | 19.6 | 4.4 | 447.0% | |
| Debt to equity ratio | x | 0 | 0.6 | 1.3% | |
| Sales to assets ratio | x | 0.8 | 0.7 | 101.6% | |
| Return on assets | % | 9.1 | 9.5 | 96.5% | |
| Return on equity | % | 13.0 | 16.5 | 78.7% | |
| Return on capital | % | 12.6 | 17.8 | 70.8% | |
| Exports to sales | % | 0 | 0 | - | |
| Imports to sales | % | 0 | 0 | - | |
| Exports (fob) | Rs m | NA | NA | - | |
| Imports (cif) | Rs m | NA | NA | - | |
| Fx inflow | Rs m | 84,193 | 62,998 | 133.6% | |
| Fx outflow | Rs m | 39,616 | 22,859 | 173.3% | |
| Net fx | Rs m | 44,577 | 40,140 | 111.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 29,841 | 13,242 | 225.4% | |
| From Investments | Rs m | -4,923 | -6,990 | 70.4% | |
| From Financial Activity | Rs m | -25,159 | -7,387 | 340.6% | |
| Net Cashflow | Rs m | -266 | -2,971 | 9.0% | |
Share Holding
| Indian Promoters | % | 25.5 | 48.3 | 52.8% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 5.4 | 6.9 | 78.3% | |
| FIIs | % | 35.3 | 34.4 | 102.6% | |
| ADR/GDR | % | 18.5 | 0.0 | - | |
| Free float | % | 15.3 | 10.5 | 145.7% | |
| Shareholders | 75,885 | 56,727 | 133.8% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. REDDYS LAB With: JUBILANT LIFE SCIENCES PANACEA BIOTECH WOCKHARDT ABBOTT INDIA FRESENIUS KABI ONCO.
Compare DR. REDDYS LAB With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Nifty is Weak but Smallcaps Can Outperform(Momentum Moves)
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
Related Views on News
GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)
Sep 1, 2020 | Updated on Sep 1, 2020For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)
Feb 19, 2020 | Updated on Feb 19, 2020For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 5, 2019 | Updated on Sep 5, 2019Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)
Jun 3, 2019 | Updated on Jun 3, 2019For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
More Views on NewsMost Popular
It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Intraday Trading for a Living(Fast Profits Daily)
Feb 15, 2021In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
Top 5 Stocks Mutual Funds Bought and Sold in January 2021(Sector Info)
Feb 16, 2021A look at what India's top equity mutual funds bought and sold in January 2021.
I Would Recommend this Small-cap Stock Over Tesla(Profit Hunter)
Feb 16, 2021Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
MoreOUR TOP 5 IDEAS
- Access Now: Eight Steps to Your Eight Figure Fortune
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
DR. REDDYS LAB SHARE PRICE
Feb 26, 2021 (Close)
TRACK DR. REDDYS LAB
- Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON DR. REDDYS LAB
DR. REDDYS LAB 8-QTR ANALYSIS
COMPARE DR. REDDYS LAB WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.